Pfizer Reorganizes Internally, Closer To Decision On Splitting Business
This article was originally published in The Tan Sheet
Executive Summary
Consumer health products are grouped with vaccines and oncology drugs in Pfizer’s internal reorganization that takes effect in January 2014. Pfizer’s realignment into three organizations represents a step in the firm’s multi-year deliberation over whether to split its business.
You may also be interested in...
Deals Of The Week: Pfizer Management Updates Thoughts On Split
Pfizer top management hasn’t yet decided whether it will divide in two or stop at a “virtual split.” Plus updates on Lundbeck/Otsuka, Shire/SARcode, AstraZeneca/Actavis, and more.
Nexium OTC Switch Would Face Crowded Field, Potential Questions
Pfizer will pay AstraZeneca $250 million upfront for global rights to market a potential OTC 20-mg Nexium. Pharma marketing expert Joe McGovern expects Nexium “to start OTC with a big bang,” but Center for Consumer Self Care Executive Director Bill Soller points to potential safety questions about a switch.
Pfizer Likes Consumer Business Fit As Segment Grows 8%
Increased sales of core brands including Advil, Caltrate and Robitussin drove up consumer sales 8% to $817 million for Pfizer’s fourth quarter. CEO Ian Read sees the segment “fitting nicely” in Pfizer following its animal health and nutrition business divestments.